Treace to Report Second Quarter 2025 Financial Results on August 7, 2025 PONTE VEDRA, Fla., July 24, 2025 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities through its flagship and Procedures, today announced that it will release financial results for the second quarter 2025 after the close of trading on Thursday, August 7, 2025. Company management will host a conference call to discuss financial results beginning at ...
Humacyte Announces First Symvess™ Sale to Military Treatment Facility Sale follows recent Electronic Catalog (ECAT) listing approval by U.S. Defense Logistics Agency Symvess now available to U.S. Department of Defense and U.S. Department of Veterans Affairs facilities DURHAM, N.C., July 23, 2025 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissue at commercial scale, announced today the first sale of Symvess to a U.S. Military Treatment Facility. The facility is a state-of...
Leggett & Platt Announces 2Q 2025 Earnings Call Carthage, MO, July 17, 2025 (GLOBE NEWSWIRE) -- Leggett & Platt (NYSE:LEG), a diversified manufacturer of engineered products serving several major markets, will release second quarter earnings results on Thursday, July 31, 2025 after the market closes, and hold its quarterly conference call to discuss second quarter results, annual guidance, market conditions, company initiatives, and related matters on Friday, August 1, 2025, at 8:30 a.m. Eastern Time (7:30 a.m. Central Time). This call will be webcast and can be accessed from the Investo...
Norwegian Cruise Line Holdings to Hold Conference Call on Second Quarter 2025 Financial Results MIAMI, July 14, 2025 (GLOBE NEWSWIRE) -- Norwegian Cruise Line Holdings Ltd. (NYSE: NCLH) (together with NCL Corporation Ltd., “Norwegian Cruise Line Holdings” or the “Company”) announced today it will report second quarter 2025 financial results on Thursday, July 31, 2025 at 6:30 a.m. Eastern Time with a conference call and webcast to discuss results at 8:00 a.m. Eastern Time. The conference call will be webcast via the Company’s Investor Relations website, . A replay of the webcast will be a...
Humacyte announces Symvess™ ECAT Approval from U.S. Defense Logistics Agency Electronic Catalog listing approval makes Symvess available to healthcare professionals at U.S. Department of Defense and U.S. Department of Veterans Affairs facilities DURHAM, N.C., July 08, 2025 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissue at commercial scale, announced today that Symvess has been awarded Electronic Catalog (ECAT) listing approval from the U.S. Defense Logistics Agency. ECAT ...
Norwegian Cruise Line Holdings Announces Upsize of its Revolving Credit Facility MIAMI, June 26, 2025 (GLOBE NEWSWIRE) -- Norwegian Cruise Line Holdings Ltd. (NYSE: NCLH) (together with NCL Corporation Ltd., “Norwegian Cruise Line Holdings” or the “Company”) announced that it has successfully upsized its existing senior secured revolving credit facility from $1.7 billion to $2.486 billion, with the existing terms and maturity date of 2030 unchanged. “The upsizing of our revolving credit facility significantly enhances our liquidity, representing another key step in further optimizing our...
In this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.
Results from Humacyte’s V007 Pivotal Phase 3 AV Access Study Highlighted by Presentation at the Society for Vascular Surgery Meeting Benefits of Humacyte’s Acellular Tissue Engineered Vessel Over Autologous Arteriovenous Fistula (AVF) in High-Risk Patients with End-Stage Kidney Disease Observed in Data Presented in Plenary Session DURHAM, N.C., June 09, 2025 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissue at commercial scale, announced today that the results from its V007 ...
Treace Files Patent Infringement Suit Against Zimmer Biomet to Protect Lapiplasty® Bunion Technology PONTE VEDRA, Fla., June 05, 2025 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities through its flagship and procedures, today announced that it filed a lawsuit against Zimmer Biomet Holdings, Inc. and Paragon 28, Inc. (collectively, “Zimmer”) (NYSE: ZBH), alleging infringement of 4 patents related to Treace’s innovativ...
Norwegian Cruise Line Holdings Releases Its 2024 “Sail & Sustain™” Report MIAMI, June 05, 2025 (GLOBE NEWSWIRE) -- Norwegian Cruise Line Holdings Ltd. (NYSE: NCLH), a leading global cruise company operating Norwegian Cruise Line, Oceania Cruises and Regent Seven Seas Cruises, today released its 2024 Sail & Sustain report. The annual report outlines the company’s efforts to continue driving a positive impact® while advancing its “Charting the Course” strategic vision. “The Sail & Sustain report reflects our ongoing commitment to responsible, long-term business practices,” said Harry Somme...
Humacyte Clinical Results in High-Risk Dialysis Patients from V007 Pivotal Phase 3 AV Access Study to be Presented at the Vascular Annual Meeting (VAM25) DURHAM, N.C., June 02, 2025 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissue at commercial scale, announced that its abstract on the V007 Pivotal Phase 3 clinical trial of the acellular tissue engineered vessel (ATEV™) in arteriovenous access for high-risk patients with end-stage renal disease was accepted for an oral pres...
Humacyte to Present at the H.C. Wainwright 3rd Annual BioConnect Investor Conference at Nasdaq DURHAM, N.C., May 19, 2025 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale, today announced that Laura Niklason, M.D., Ph.D., Founder, President, and Chief Executive Officer, will present at the H.C. Wainwright 3rd Annual BioConnect Investor Conference at Nasdaq in New York, NY on Tuesday, May 20, 2025. Management will also be available for one-on-one meetings....
Humacyte Announces First Quarter 2025 Financial Results and Provides Business Update - Commenced market launch and first commercial sales of Symvess™ (acellular tissue engineered vessel-tyod) for the treatment of extremity vascular trauma - - Total revenues of $517,000 for quarter from sales and collaborative research agreement – - Completed public offering raising $46.7 million in net proceeds - - Implemented cost reduction to extend cash runway - ---Conference call today at 8:30am ET - DURHAM, N.C., May 13, 2025 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stag...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.